367Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Germany
Neuroscience Intelligence
Germany neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #6 of 50 · Data maturity A · Research score 50.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
82Recruiting trials
752Publications
447Institutions
Executive interpretation
Germany ranks #6 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC177 recruiting
Charite University, Berlin, Germany142 recruiting
Hoffmann-La Roche134 recruiting
Pfizer81 recruiting
University Hospital Muenster80 recruiting
UCB Pharma80 recruiting
Ludwig-Maximilians - University of Munich73 recruiting
University Hospital Tuebingen70 recruiting
GlaxoSmithKline60 recruiting
Biogen61 recruiting
Disease activity
Parkinsons67trials
Epilepsy44trials
Alzheimers41trials
Stroke31trials
Other Neurology24trials
Depression18trials
Neuromuscular14trials
Other Psychiatry10trials
Schizophrenia10trials
Adhd9trials
Research institutions
Segeberger KlinikenOpenAlexlinked institution
Weierstrass Institute for Applied Analysis and StochasticsOpenAlexlinked institution
German Cardiac SocietyOpenAlexlinked institution
PHV DialysezentrumOpenAlexlinked institution
University Hospital LeipzigOpenAlexlinked institution
Universitäts-Herzzentrum Freiburg-Bad KrozingenOpenAlexlinked institution
Federal Institute for Population ResearchOpenAlexlinked institution
Richard Wolf (Germany)OpenAlexlinked institution
Kerckhoff KlinikOpenAlexlinked institution
Klinikum Links der WeserOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07586150Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)NOT_YET_RECRUITING
NCT07395206Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum DisordersRECRUITING
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRECRUITING
NCT07299448Biological Determinants and Neural Compensation of Dysphagia in Parkinson's DiseaseRECRUITING
NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT07009990Coronary and Cerebral Microvascular Dysfunction in Neurological DiseasesNOT_YET_RECRUITING
Research evidence trail
PUBMEDFrom gut to brain: data-driven evidence suggests causal contribution of gut-microbiota to major depressive disorder in humans.2026-12-31
PUBMEDFactors associated with long-term posttraumatic stress following later termination of pregnancy for fetal anomaly: results from a longitudinal study.2026-12-31
PUBMEDFeasibility and acceptability of modular empowerment group therapy in Ukrainian adult outpatients: A pilot study.2026-12-15
PUBMEDNegative expectations in major depression: Association with brain structure and course of illness.2026-12-15
PUBMEDMechanistic characterization and inhibition of PAD4-dependent NETosis following experimental neonatal hypoxic-ischemic brain injury.2026-12-01
PUBMEDCue-induced inhibitory control in forensic patients with alcohol use disorder: A link to criminal recidivism risk assessed by factor 2 psychopathy.2026-12-01
PUBMEDDo subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.2026-12-01
PUBMEDOnly the real deal? Actual vs. virtual nature exposure and their effects on affect and cortical hemodynamics in health and major depression.2026-12-01
PUBMEDComparing trajectories of cognitive functioning in treatment-resistant and non-resistant depression: a multicentre linear mixed-effects analysis.2026-12-01
PUBMEDEmotional processing biases in the longitudinal course of major depressive disorder.2026-12-01
PUBMEDPharmacological treatment of late-life major depressive disorder - Results from the AMSP drug surveillance program from 2007 to 2023.2026-12-01
PUBMEDThe "salted pretzel" sign: A radiological indication of a calcified amorphous tumor as a rare cause of embolic stroke.2026-12-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.